EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways

Mikel Gurrea-Rubio, Qin Wang, Elizabeth A Mills, Qi Wu, David Pitt, Pei-Suen Tsou iD, David A Fox, Yang Mao-Draayer

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25052454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mikel Gurrea-Rubio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Neuroprotective Agents, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Azetidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIAID NIH HHS, NIH NIAID Autoimmune Center of Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS), consisting of heterogeneous clinical courses varying from relapsing-remitting MS (RRMS), in which disability is linked to bouts of inflammation, to progressive disease such as primary progressive MS (PPMS) and secondary progressive MS (SPMS), in which neurological disability is thought to be linked to neurodegeneration. As a result, successful therapeutics for progressive MS likely need to have both anti-inflammatory and direct neuroprotective properties. The modulation of sphingosine-1-phosphate (S1P) receptors has been implicated in neuroprotection in preclinical animal models. Siponimod/BAF312, the first oral treatment approved for SPMS, may have direct neuroprotective benefits mediated by its activity as a selective (S1P receptor 1) S1P1 and (S1P receptor 5) S1P5 modulator. We showed that S1P1 was mainly present in cortical neurons in lesioned areas of the MS brain. To gain a better understanding of the neuroprotective effects of siponimod in MS, we used both rat neurons and human-induced pluripotent stem cell (iPSC)-derived neurons treated with the neuroinflammatory cytokine tumor necrosis factor-alpha (TNF-α). Cell survival/apoptotic assays using flow cytometry and IncuCyte live cell analyses showed that siponimod decreased TNF-α induced neuronal cell apoptosis in both rat and human iPSCs. Importantly, a transcriptomic analysis revealed that mitochondrial oxidative phosphorylation, NFκB and cytokine signaling pathways contributed to siponimod’s neuroprotective effects. Our data suggest that the neuroprotection of siponimod/BAF312 likely involves the relief of oxidative stress in neuronal cells. Further studies are needed to explore the molecular mechanisms of such interactions to determine the relationship between mitochondrial dysfunction and neuroinflammation/neurodegeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsMultiple SclerosisMultiple Sclerosis, Chronic ProgressiveAzetidinesBenzyl CompoundsHumansAnimalsRatsSphingosine-1-Phosphate ReceptorsNeuroinflammatory DiseasesTumor Necrosis Factor-alphaCell Death

Stichwörter der Autor:innen

MAPK/NFκBhuman neural stem/progenitor cells (hNSCs/NPCs)multiple sclerosis (MS)neuroprotectionoxidative stress

Substanzen

siponimodSphingosine-1-Phosphate ReceptorsNeuroprotective AgentsTumor Necrosis Factor-alphaAzetidinesBenzyl Compounds

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Neurology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Autoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Department of Neurology, Yale Medicine, New Haven, CT 06473, USA.
  • Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.

ORCID-Profile: Pei-Suen Tsou

Förderung

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • NIH NIAID Autoimmune Center of Excellence

Zitieren

APA

Gurrea-Rubio, M., Wang, Q., Mills, E. A., Wu, Q., Pitt, D., Tsou, P. S., Fox, D. A., & Mao-Draayer, Y. (2024). Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052454

Vancouver

Gurrea-Rubio M, Wang Q, Mills EA, Wu Q, Pitt D, Tsou PS, et al. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052454

BibTeX
@article{GurreaRubio2024,
  author = {Gurrea-Rubio, Mikel and Wang, Qin and Mills, Elizabeth A and Wu, Qi and Pitt, David and Tsou, Pei-Suen and Fox, David A and Mao-Draayer, Yang},
  title = {Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25052454}
}
Kostenlos starten →